Literature DB >> 20594104

Oseltamivir dosing for influenza infection in premature neonates.

Edward P Acosta1, Penelope Jester, Peter Gal, John Wimmer, Joni Wade, Richard J Whitley, David W Kimberlin.   

Abstract

Under the Emergency Use Authorization issued in April 2009, oseltamivir can be used to treat 2009 influenza A (H1N1) virus infection in children aged <1 year. No data exist on the dosing of oseltamivir in premature babies. A hospital health care worker inadvertently exposed 32 neonatal intensive care unit babies to 2009 influenza A (H1N1); a protocol was expeditiously implemented to collect samples for pharmacokinetics and dosage evaluation. Results suggest 1.0 mg/kg/dose twice daily in premature babies produces oseltamivir carboxylate exposures similar to that in older children receiving 3.0 mg/kg/dose twice daily. These results provide initial guidance on dosing oseltamivir in this vulnerable population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594104      PMCID: PMC2904429          DOI: 10.1086/654930

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

Review 1.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

2.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Authors:  H Wiltshire; B Wiltshire; A Citron; T Clarke; C Serpe; D Gray; W Herron
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-08-18

3.  Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.

Authors:  Charles Oo; George Hill; Albert Dorr; Baolian Liu; Samuel Boellner; Penelope Ward
Journal:  Eur J Clin Pharmacol       Date:  2003-08-09       Impact factor: 2.953

Review 4.  Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Authors:  Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

  4 in total
  23 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Influenza A/H1N1/09-10 infections in a NICU during the 2009-2010 H1N1 pandemic.

Authors:  Navin K Vij; Christopher C Stryker; Frank P Esper; Michael R Jacobs; Blanca E Gonzalez
Journal:  Pediatrics       Date:  2011-10-03       Impact factor: 7.124

3.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

4.  Oseltamivir dosing in premature infants.

Authors:  Christopher McPherson; Barbara Warner; David A Hunstad; Alexis Elward; Edward P Acosta
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

Review 5.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

Review 6.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

7.  The use of antiviral drugs for influenza: Guidance for practitioners, 2012/2013; Paediatric summary.

Authors:  Upton D Allen
Journal:  Paediatr Child Health       Date:  2013-03       Impact factor: 2.253

8.  Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.

Authors:  David W Kimberlin; Edward P Acosta; Mark N Prichard; Pablo J Sánchez; Krow Ampofo; David Lang; Negar Ashouri; John A Vanchiere; Mark J Abzug; Nazha Abughali; Mary T Caserta; Janet A Englund; Sunil K Sood; Michael G Spigarelli; John S Bradley; Judy Lew; Marian G Michaels; Wen Wan; Gretchen Cloud; Penelope Jester; Fred D Lakeman; Richard J Whitley
Journal:  J Infect Dis       Date:  2012-12-10       Impact factor: 5.226

9.  The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013.

Authors:  Fred Y Aoki; Upton D Allen; H Grant Stiver; Gerald A Evans
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

Review 10.  Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Authors:  Ashit Trivedi; Richard E Lee; Bernd Meibohm
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.